Pcn181 - Cost-Utility Analysis of Adjuvant Pertuzumab-Based Regimen in Women With Her2-Positive Breast Cancer in Italy

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.264
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines

BMC Health Services Research
Health Policy
2019English

Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Cost-Utility Analysis of Adjuvant Therapies for Breast Cancer in Iran

International Journal of Technology Assessment in Health Care
Health Policy
2012English

Safety Assessment of Neoadjuvant Pertuzumab Combined With Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia

International Journal of Breast Cancer
Cancer ResearchOncologyPharmacology
2018English

Oncofertility Counselling in Premenopausal Women With HER2-positive Breast Cancer

Oncotarget
Oncology
2019English

Estimated Life-Years Saved in Women With HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

AboutOpen
2018English

Neratinib in Adjuvant Treatment of Patients With HER2-positive Breast Cancer — Less Is More?

Oncology in Clinical Practice
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy